6 recruiting, 4 completed, 3 terminated, 3 unknown. 9 Phase 2, 5 Not applicable, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Recruiting 3, Unknown 2, Active not recruiting 1 |
| Not applicable | 5 | Recruiting 3, Completed 1, Terminated 1 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Cholangiocarcinoma Non-resectable: new trials by email Literature Review of Cholangiocarcinoma Non-resectable trials Research Report on Cholangiocarcinoma Non-resectable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma Preoperative Right Hepatic Artery Embolization - Cholangiocarcinoma Non-resectable | Not applicable | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 33 | 2026-04-01 | 2026-11-09 |
| TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) | Not yet recruiting | Aarhus University Hospital | 300 | 2026-03-15 | 2026-03-06 | |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | Phase 1 | Terminated | Context Therapeutics Inc. | 19 | 2025-03-31 | 2026-11-05 |
| En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria Liver transplantation after en bloc resection of the liver and pancreas - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent | Not applicable | Recruiting | Oslo University Hospital | 15 | 2025-01-01 | 2025-08-21 |
| Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma HAIC, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Recruiting | Tongji Hospital | 36 | 2024-06-04 | 2026-07-22 |
| Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 30 | 2024-02-13 | 2026-04-22 |
| Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma DEB-TACE, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Unknown | Tongji Hospital | 36 | 2023-12-09 | 2024-01-09 |
| A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Ivosidenib - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Active not recruiting | Servier | 12 | 2023-10-10 | 2025-12-09 |
| Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction Primary percutaneous stenting (PPS), Endoscopic biliary drainage - Cholangiocarcinoma Non-resectable, Gall Bladder Cancer | Phase 3 | Enrolling by invitation | Erasmus Medical Center | 148 | 2023-08-09 | 2024-11-04 |
| Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer Candonilimab, Cisplatin, Gemcitabine - Cholangiocarcinoma Non-resectable | Phase 2 | Unknown | West China Hospital | 65 | 2023-07-01 | 2023-08-07 |
| DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1 - Cholangiocarcinoma Non-resectable | Unknown | Ze-yang Ding, MD | 100 | 2022-02-01 | 2024-01-09 | |
| Photodynamic Therapy for Cholangiocarcinoma Hematoporphyrin - Cholangiocarcinoma Non-resectable | Not applicable | Completed | Hepatopancreatobiliary Surgery Institute of Gansu Province | 86 | 2021-04-17 | 2024-11-20 |
| TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors TACE with ICI - Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable | Not applicable | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2020-10-27 | 2024-07-05 |
| Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy - Cholangiocarcinoma Non-resectable, Non-metastatic | Phase 2 | Recruiting | University Hospital, Montpellier | 40 | 2018-06-11 | 2026-01-05 |
| Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 128 | 2018-05-02 | 2023-06-15 |
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma ABC294640, Hydroxychloroquine Sulfate 200 MG - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable | Phase 2 | Completed | RedHill Biopharma Limited | 65 | 2018-03-07 | 2025-07-23 |
| Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies nal-IRI, 5-FU, leucovorin - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Completed | AIO-Studien-gGmbH | 100 | 2017-10-24 | 2022-05-18 |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
| RFA RCT for Pancreatic or Bile Duct Cancer Radiofrequency Ablation using EndoHPB Probe, Stenting only - Unresectable Pancreatic Cancer, Cholangiocarcinoma Non-resectable | Not applicable | Terminated | Weill Medical College of Cornell University | 8 | 2014-06-01 | 2019-09-30 |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) ABC294640 - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable | No longer available | RedHill Biopharma Limited | 2025-03-18 |
Cholangiocarcinoma (12) · Klatskin Tumor (5) · Gallbladder Neoplasms (3) · Neoplasms (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Pancreatic Neoplasms (1)
Carcinoma (15) · Neoplasms by Histologic Type (15) · Neoplasms, Glandular and Epithelial (15) · Adenocarcinoma (14) · Neoplasms (14) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Neoplasms by Site (7) · Biliary Tract Diseases (4) · Biliary Tract Neoplasms (3) · Gallbladder Diseases (3) · Cholangiocarcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplastic Processes (2)
Cisplatin (3) · Gemcitabine (3) · 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (2) · durvalumab (2) · lenvatinib (2) · Fluorouracil (1) · Hematoporphyrins (1) · Hydroxychloroquine (1) · Leucovorin (1) · PEGPH20 (1) · Pancreatic Hormones (1) · Yttrium-90 (1) · atezolizumab (1) · gemcitabine-oxaliplatin regimen (1) · irinotecan sucrosofate (1)
AIO-Studien-gGmbH (2) · RedHill Biopharma Limited (2) · Tongji Hospital (2) · Aarhus University Hospital (1) · Beth Israel Deaconess Medical Center (1) · Context Therapeutics Inc. (1) · Erasmus Medical Center (1) · Halozyme Therapeutics (1) · Hepatopancreatobiliary Surgery Institute of Gansu Province (1) · Oslo University Hospital (1) · Servier (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University Hospital, Montpellier (1) · Weill Medical College of Cornell University (1)
China (7) · United States (5) · Germany (2) · Denmark (1) · France (1) · Japan (1) · Netherlands (1) · Norway (1) · South Korea (1) · Thailand (1)
Ze-yang Ding, M.D. (2) · Andrea Bullock, MD, MPH (1) · Arndt Vogel, Prof. (1) · Arndt Vogel, Prof. Dr. (1) · Karen Chagin, MD (1) · Karen-Lise Garm Spindler, Professor, MD, PhD (1) · Lise Thorsen, Associate professor, MD, PhD (1) · Mitesh Borad, MD (1) · Mohamed Metwally, Consultant, MD, PhD (1) · Reem Z Sharaiha, MD (1) · Xun Li, M.D.,Ph.D. (1) · Ze-yang Ding (1)
PMID 28420720, PMID 40812353, PMID 38870977, PMID 40147791, PMID 40346549
2016 (1), 2017 (1)